NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, Price Target & More

$5.05 +0.18 (+3.70 %)
(As of 04/26/2018 11:48 AM ET)
Previous Close$4.87
Today's Range$4.89 - $5.10
52-Week Range$3.95 - $7.39
Volume134,167 shs
Average Volume1.09 million shs
Market Capitalization$479.69 million
P/E Ratio-6.24
Dividend YieldN/A
Beta2.71

About BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Debt-to-Equity Ratio0.23%
Current Ratio1.68%
Quick Ratio1.68%

Price-To-Earnings

Trailing P/E Ratio-6.24
Forward P/E Ratio-6.39
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.19 million
Price / Sales19.79
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book5.94

Profitability

EPS (Most Recent Fiscal Year)($0.78)
Net Income$-65,780,000.00
Net Margins-261.18%
Return on Equity-106.53%
Return on Assets-42.94%

Miscellaneous

Employees85
Outstanding Shares98,700,000

How to Become a New Pot Stock Millionaire

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.06. The biotechnology company had revenue of $3.89 million for the quarter, compared to analysts' expectations of $6.07 million. BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. BioCryst Pharmaceuticals's revenue for the quarter was down 56.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.06) earnings per share. View BioCryst Pharmaceuticals' Earnings History.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for BioCryst Pharmaceuticals.

What price target have analysts set for BCRX?

8 equities research analysts have issued 1-year price objectives for BioCryst Pharmaceuticals' stock. Their predictions range from $6.00 to $15.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $8.8333 in the next twelve months. View Analyst Ratings for BioCryst Pharmaceuticals.

What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (3/5/2018)
  • 2. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)
  • 3. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 11,058,975 shares, a decline of 8.2% from the February 28th total of 12,044,486 shares. Based on an average trading volume of 966,749 shares, the days-to-cover ratio is currently 11.4 days. Approximately 11.4% of the shares of the company are short sold.

Who are some of BioCryst Pharmaceuticals' key competitors?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the folowing people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 57)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 50)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 63)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 65)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 51)

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

Media stories about BCRX stock have trended positive on Thursday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.94 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include GREAT POINT PARTNERS LLC (7.60%), GREAT POINT PARTNERS LLC (7.60%), RA CAPITAL MANAGEMENT, LLC (7.10%) and RA CAPITAL MANAGEMENT, LLC (7.10%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Fred E Cohen, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $5.05.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $479.69 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]


MarketBeat Community Rating for BioCryst Pharmaceuticals (BCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for BioCryst Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8333, suggesting that the stock has a possible upside of 74.92%. The high price target for BCRX is $15.00 and the low price target for BCRX is $6.00. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.672.70
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.8333$8.8333$9.1429$9.25
Price Target Upside: 74.92% upside66.04% upside71.86% upside79.26% upside

BioCryst Pharmaceuticals (NASDAQ:BCRX) Consensus Price Target History

Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018HC WainwrightReiterated RatingBuy$10.00MediumView Rating Details
1/2/2018Royal Bank of CanadaUpgradeSector Perform -> Outperform$6.00HighView Rating Details
12/20/2017BarclaysInitiated CoverageEqual Weight -> Equal Weight$6.00MediumView Rating Details
9/6/2017JPMorgan ChaseBoost Price TargetOverweight -> Neutral$4.93 -> $9.00HighView Rating Details
9/6/2017Jefferies GroupUpgradeHold -> Buy$5.00 -> $7.00HighView Rating Details
9/5/2017Piper JaffrayReiterated RatingOverweight$13.00 -> $15.00HighView Rating Details
8/8/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/19/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/16/2017Ladenburg ThalmannInitiated CoverageBuy$11.00N/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/16/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Earnings History and Estimates Chart

Earnings by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.22)($0.22)($0.22)
Q4 20181($0.24)($0.24)($0.24)

BioCryst Pharmaceuticals (NASDAQ BCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.20)N/AView Earnings Details
2/27/2018Q4 2017($0.14)($0.20)$6.07 million$3.89 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.18)($0.18)$5.05 million$8.76 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.21)$5.79 million$3.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.20)($0.19)$6.13 million$9.40 millionViewListenView Earnings Details
2/27/2017Q416($0.23)($0.06)$4.13 million$9.00 millionViewListenView Earnings Details
11/7/2016Q316($0.24)($0.16)$5.94 million$7.80 millionViewListenView Earnings Details
8/4/2016Q216($0.26)($0.22)$3.92 million$4.80 millionViewN/AView Earnings Details
5/5/2016Q116($0.23)($0.31)$5.42 million$4.82 millionViewN/AView Earnings Details
2/23/2016Q415($0.26)($0.25)$6.34 million$4.60 millionViewListenView Earnings Details
11/5/2015Q315($0.20)($0.20)$6.77 million$11.00 millionViewListenView Earnings Details
8/7/2015Q215($0.22)$0.06$7.10 million$25.80 millionViewListenView Earnings Details
5/8/2015Q115($0.24)($0.21)$4.30 million$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.20)($0.16)$3.64 million$5.40 millionViewListenView Earnings Details
11/6/2014Q314($0.20)($0.12)$2.11 million$3.20 millionViewListenView Earnings Details
8/5/2014Q214($0.19)($0.23)$2.32 million$1.50 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)($0.17)$3.34 million$3.50 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.09)$8.81 million$10.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.14)($0.14)$2.01 million$2.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.23)$2.01 million$0.82 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.15)($0.09)$1.31 million$3.60 millionViewN/AView Earnings Details
2/19/2013Q4 2012($0.16)($0.22)$4.02 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.19)$4.63 million$5.80 millionViewN/AView Earnings Details
8/2/2012($0.26)($0.25)ViewN/AView Earnings Details
5/7/2012($0.26)($0.13)ViewN/AView Earnings Details
2/16/2012($0.33)($0.29)ViewN/AView Earnings Details
11/2/2011($0.30)($0.32)ViewN/AView Earnings Details
8/4/2011($0.26)($0.36)ViewN/AView Earnings Details
5/4/2011($0.20)($0.29)ViewN/AView Earnings Details
2/10/2011($0.21)($0.20)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.17)($0.24)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.24)($0.23)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.16)($0.06)ViewN/AView Earnings Details
2/4/2010Q4 2009$0.08$0.35ViewN/AView Earnings Details
10/29/2009Q3 2009($0.22)($0.28)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.25)($0.23)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.28)($0.24)ViewN/AView Earnings Details
2/6/2009Q4 2008($0.22)$0.26ViewN/AView Earnings Details
10/31/2008Q3 2008($0.25)($0.24)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.20)($0.33)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.16)($0.34)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.39)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioCryst Pharmaceuticals (NASDAQ:BCRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 91.45%
Insider Trading History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017William P SheridanCMOSell64,310$4.72$303,543.20View SEC Filing  
9/18/2017Fred E CohenDirectorSell54,250$5.42$294,035.00173,660View SEC Filing  
3/20/2017Thomas R Staab IICFOSell3,250$9.20$29,900.00144,710View SEC Filing  
3/10/2017Thomas R Staab IIInsiderSell3,250$9.06$29,445.00120,563View SEC Filing  
3/8/2017Thomas R Staab IIInsiderSell6,500$8.43$54,795.00123,813View SEC Filing  
3/6/2017Thomas R Staab IIInsiderSell3,250$7.90$25,675.00120,563View SEC Filing  
12/19/2016Thomas R Staab IIInsiderSell3,250$7.45$24,212.50127,437View SEC Filing  
9/14/2016Alane P BarnesVPSell8,357$4.27$35,684.3979,377View SEC Filing  
8/25/2016Yarlagadda S BabuVPSell30,000$4.06$121,800.00111,428View SEC Filing  
8/16/2016Bros. Advisors Lp BakerMajor ShareholderSell4,046,590$5.00$20,232,950.00View SEC Filing  
8/12/2016Thomas R Staab IIInsiderSell5,864$5.18$30,375.52128,745View SEC Filing  
8/9/2016Thomas R Staab IIInsiderSell14,577$4.43$64,576.11130,051View SEC Filing  
1/28/2016Bros. Advisors Lp Bakermajor shareholderBuy88,345$6.95$613,997.7523,459View SEC Filing  
1/22/2016Bros. Advisors Lp Bakermajor shareholderBuy106,800$7.28$777,504.0023,459View SEC Filing  
1/20/2016Bros. Advisors Lp Bakermajor shareholderBuy52,695$6.87$362,014.6523,459View SEC Filing  
1/19/2016Bros. Advisors Lp Bakermajor shareholderBuy92,200$7.12$656,464.0023,459View SEC Filing  
1/15/2016Bros. Advisors Lp Bakermajor shareholderBuy200,000$7.46$1,492,000.0023,459View SEC Filing  
12/21/2015Thomas R Staab IICFOSell3,052$10.86$33,144.72136,592View SEC Filing  
12/17/2015Thomas R Staab IICFOSell3,000$10.49$31,470.00139,644View SEC Filing  
7/20/2015Thomas R Staab IICFOSell3,500$16.50$57,750.00View SEC Filing  
6/22/2015Thomas R Staab IICFOSell3,750$16.00$60,000.00View SEC Filing  
6/19/2015Alane P BarnesVPSell3,000$15.00$45,000.00View SEC Filing  
6/19/2015Jon P StonehouseCEOSell20,000$15.02$300,400.00View SEC Filing  
6/19/2015Thomas R Staab IICFOSell16,375$14.36$235,145.00View SEC Filing  
6/19/2015William P SheridanCMOSell70,389$15.05$1,059,354.45View SEC Filing  
6/5/2015Thomas R Staab IICFOSell6,000$12.75$76,500.00View SEC Filing  
5/18/2015Thomas R Staab IICFOSell3,000$11.00$33,000.00View SEC Filing  
3/19/2015Yarlagadda S BabuVPSell12,105$10.16$122,986.80View SEC Filing  
3/5/2015Yarlagadda S BabuVPSell37,400$10.59$396,066.00View SEC Filing  
3/4/2015Yarlagadda S BabuVPSell10,495$10.50$110,197.50View SEC Filing  
2/20/2015Nancy J HutsonDirectorBuy10,000$10.27$102,700.00View SEC Filing  
12/30/2014William P SheridanCMOSell128,399$12.36$1,587,011.64View SEC Filing  
12/29/2014Thomas R Staab IICFOSell9,500$12.56$119,320.00View SEC Filing  
12/29/2014William P SheridanCMOSell105,295$12.43$1,308,816.85View SEC Filing  
8/27/2014Thomas R Staab IICFOSell10,000$13.58$135,800.00View SEC Filing  
7/1/2014Thomas R Staab IICFOSell3,125$13.00$40,625.00View SEC Filing  
6/23/2014Thomas R Staab IICFOSell3,125$12.49$39,031.25View SEC Filing  
6/17/2014Thomas R Staab IICFOSell3,125$12.00$37,500.00View SEC Filing  
3/14/2014Thomas Staab IICFOSell3,125$11.24$35,125.00126,616View SEC Filing  
3/6/2014Kenneth Lee, Jr.DirectorSell12,665$12.69$160,718.8510,252View SEC Filing  
11/12/2013George AbercrombieDirectorBuy3,000$6.19$18,570.006,000View SEC Filing  
8/1/2013Felix BakerMajor ShareholderBuy1,136,364$4.40$5,000,001.60View SEC Filing  
3/5/2013George B AbercrombieDirectorBuy3,000$1.23$3,690.00View SEC Filing  
12/14/2012Peder JensenDirectorBuy20,000$1.51$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioCryst Pharmaceuticals (NASDAQ BCRX) News Headlines

Source:
DateHeadline
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on WednesdayBioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 5:46 AM
BioCryst Pharmaceuticals (BCRX) Expected to Post Quarterly Sales of $10.20 MillionBioCryst Pharmaceuticals (BCRX) Expected to Post Quarterly Sales of $10.20 Million
www.americanbankingnews.com - April 21 at 3:50 AM
-$0.16 Earnings Per Share Expected for BioCryst Pharmaceuticals (BCRX) This Quarter-$0.16 Earnings Per Share Expected for BioCryst Pharmaceuticals (BCRX) This Quarter
www.americanbankingnews.com - April 19 at 1:18 PM
Contrasting Voyager Therapeutics (VYGR) and BioCryst Pharmaceuticals (BCRX)Contrasting Voyager Therapeutics (VYGR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 18 at 5:15 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from BrokeragesBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 15 at 1:40 PM
BioCryst Pharmaceuticals (BCRX) Upgraded at BidaskClubBioCryst Pharmaceuticals (BCRX) Upgraded at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM
BioCryst Pharmaceuticals (BCRX) Stock Rating Reaffirmed by HC WainwrightBioCryst Pharmaceuticals (BCRX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM
Noble Financial Reiterates "Buy" Rating for BioCryst Pharmaceuticals (BCRX)Noble Financial Reiterates "Buy" Rating for BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 11 at 8:27 PM
ValuEngine Lowers BioCryst Pharmaceuticals (BCRX) to SellValuEngine Lowers BioCryst Pharmaceuticals (BCRX) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM
BioCryst and Idera postpone shareholder meetings for merger vote until July 10BioCryst and Idera postpone shareholder meetings for merger vote until July 10
seekingalpha.com - April 10 at 8:26 AM
 Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $10.20 Million Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $10.20 Million
www.americanbankingnews.com - April 4 at 2:50 AM
-$0.16 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter-$0.16 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - April 2 at 1:15 PM
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (BCRX)HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 1 at 10:34 AM
BioCryst Pharmaceuticals (BCRX) Raised to "Outperform" at Royal Bank of CanadaBioCryst Pharmaceuticals (BCRX) Raised to "Outperform" at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:54 PM
Short Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 8.2%Short Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 8.2%
www.americanbankingnews.com - March 30 at 2:26 AM
Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMTEdited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT
finance.yahoo.com - March 29 at 8:27 AM
Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX)Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX)
feeds.benzinga.com - March 24 at 1:48 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:18 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Recommendation of "Hold" from AnalystsBioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 1:40 PM
BioCryst Pharmaceuticals (BCRX) and Pharming Group (PHGUF) Head to Head ContrastBioCryst Pharmaceuticals (BCRX) and Pharming Group (PHGUF) Head to Head Contrast
www.americanbankingnews.com - March 18 at 5:18 PM
$10.20 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter$10.20 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - March 18 at 5:57 AM
 Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.16 EPS Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.16 EPS
www.americanbankingnews.com - March 16 at 11:42 AM
BioCryst Pharma (BCRX) Reports Initiation of Phase 3 APeX-2 Trial of BCX7353 - StreetInsider.comBioCryst Pharma (BCRX) Reports Initiation of Phase 3 APeX-2 Trial of BCX7353 - StreetInsider.com
www.streetinsider.com - March 15 at 8:16 AM
BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary AngioedemaBioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
finance.yahoo.com - March 15 at 8:16 AM
Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic AcidBlog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid
finance.yahoo.com - March 9 at 8:20 AM
BioCryst Pharmaceuticals, Inc. (BCRX) Holdings Trimmed by VHCP Management II LLCBioCryst Pharmaceuticals, Inc. (BCRX) Holdings Trimmed by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:50 AM
BioCryst Pharmaceuticals (BCRX) Cut to Sell at Zacks Investment ResearchBioCryst Pharmaceuticals (BCRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 5 at 6:12 PM
Q1 2018 Earnings Estimate for BioCryst Pharmaceuticals, Inc. Issued By Jefferies Group (BCRX)Q1 2018 Earnings Estimate for BioCryst Pharmaceuticals, Inc. Issued By Jefferies Group (BCRX)
www.americanbankingnews.com - March 5 at 2:56 AM
Emory University Has $1.88 Million Position in BioCryst Pharmaceuticals, Inc. (BCRX)Emory University Has $1.88 Million Position in BioCryst Pharmaceuticals, Inc. (BCRX)
www.americanbankingnews.com - March 4 at 2:59 PM
Analysts Offer Predictions for BioCryst Pharmaceuticals, Inc.s FY2022 Earnings (BCRX)Analysts Offer Predictions for BioCryst Pharmaceuticals, Inc.'s FY2022 Earnings (BCRX)
www.americanbankingnews.com - March 2 at 5:32 PM
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 ... - Seeking AlphaBioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 ... - Seeking Alpha
seekingalpha.com - February 28 at 8:17 AM
BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary AngioedemaBioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
finance.yahoo.com - February 28 at 8:17 AM
BioCryst Reports Fourth Quarter and Full Year 2017 Financial ResultsBioCryst Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:55 PM
Does BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) Earnings Growth Make It An Outperformer?Does BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) Earnings Growth Make It An Outperformer?
finance.yahoo.com - February 27 at 5:55 PM
BioCryst Pharmaceuticals (BCRX) Releases Quarterly  Earnings Results, Misses Estimates By $0.05 EPSBioCryst Pharmaceuticals (BCRX) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - February 27 at 11:31 AM
BioCryst Pharmaceuticals misses by $0.05, misses on revenueBioCryst Pharmaceuticals misses by $0.05, misses on revenue
seekingalpha.com - February 27 at 8:37 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in ... - GlobeNewswire (press release)BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in ... - GlobeNewswire (press release)
www.globenewswire.com - February 27 at 8:18 AM
Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - February 27 at 8:18 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending MergerBioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
finance.yahoo.com - February 27 at 8:18 AM
Options Traders Expect Huge Moves in BioCryst (BCRX) StockOptions Traders Expect Huge Moves in BioCryst (BCRX) Stock
finance.yahoo.com - February 26 at 5:45 PM
Why significant BioCryst shareholder plans to vote against Idera merger - Triangle Business JournalWhy significant BioCryst shareholder plans to vote against Idera merger - Triangle Business Journal
www.bizjournals.com - February 21 at 8:21 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences - GlobeNewswire (press release)BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 20 at 8:16 AM
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor ConferencesBioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
feeds.benzinga.com - February 19 at 2:31 PM
Contrasting Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)Contrasting Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - February 19 at 1:20 PM
BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on MondayBioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:10 AM
Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. - PR Newswire (press release)Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. - PR Newswire (press release)
www.prnewswire.com - February 17 at 8:13 AM
BioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngineBioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 14 at 11:42 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $6.63 MillionBioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $6.63 Million
www.americanbankingnews.com - February 12 at 4:30 AM
BioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClubBioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 10:16 PM
BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of "Hold" by BrokeragesBioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 30 at 1:32 PM

SEC Filings

BioCryst Pharmaceuticals (NASDAQ:BCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioCryst Pharmaceuticals (NASDAQ:BCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioCryst Pharmaceuticals (NASDAQ BCRX) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.